Association between eight P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinemiaGeers, L. M., Pozhidaev, I. V., Ivanova, S. A., Freidin, M. B., Schmidt, A. F., Cohen, D., Boiko, A. S., Paderina, D. Z., Fedorenko, O. Y., Semke, A. V., Bokhan, N. A., Wilffert, B., Kosterink, J. G. W., Touw, D. J. & Loonen, A. J. M., 21-Mar-2020, In : British Journal of Clinical Pharmacology. 9 p.
Research output: Contribution to journal › Article › Academic › peer-review
- PharmacoTherapy, Epidemiology and Economics
- Reproductive Origins of Adult Health and Disease (ROAHD)
- Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Biopharmaceuticals, Discovery, Design and Delivery (BDDD)
- Targeted Gynaecologic Oncology (TARGON)
- Groningen Research Institute for Asthma and COPD (GRIAC)
- Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE)
- Pharmaceutical Analysis
- Pharmacotherapy and Pharmaceutical Care
INTRODUCTION: Hyperprolactinemia, a common adverse effect of antipsychotic drugs, is primarily linked to blockade of dopamine D2 receptors in the pituitary gland. Certain antipsychotic drugs, like for example risperidone and paliperidone, are more likely to induce hyperprolactinemia compared to others. This effect is probably caused by a relatively high blood/brain concentration ratio, a consequence of being a substrate of P-glycoprotein. Genetic variants of P-glycoprotein with changed functional activity might influence the potential of risperidone and paliperidone to cause hyperprolactinemia as the altered blood/brain concentration ratio would lead to a reduced therapeutic drug level within essential brain areas making dose adaptations necessary. This increases exposure of dopamine D2 receptors within the pituitary gland.
AIM: To investigate possible associations between MDR1/ABCB1 gene-polymorphisms and antipsychotic drug-induced hyperprolactinemia in Russian patients with schizophrenia and to determine possible differences between risperidone/paliperidone and other antipsychotics.
METHOD: 446 patients with schizophrenia were included from three psychiatric hospitals in Siberia. Blood samples were obtained in a cross-sectional study design for DNA extraction and prolactin measurement. Associations between hyperprolactinemia and eight MDR1/ABCB1 gene-polymorphisms were assessed using logistic regression analysis accounting for covariates. The analysis was repeated in a patient subgroup using risperidone or paliperidone.
RESULTS: We did not observe an association between any of the eight SNPs and the prevalence of antipsychotic-induced hyperprolactinemia in the total patient population. However, in the risperidone/paliperidone subgroup, the SNP rs2032582 (G2677T) was found to be negatively associated with risperidone/paliperidone-induced hyperprolactinemia.
CONCLUSION: This study revealed a significant association between the ABCB1 gene polymorphism rs2032582 (G2677T) and risperidone/paliperidone-induced hyperprolactinemia.
|Number of pages||9|
|Journal||British Journal of Clinical Pharmacology|
|Publication status||E-pub ahead of print - 21-Mar-2020|